Fights Cancer

There’s also a good deal of evidence supporting the anti-cancer and anti-tumor properties of cabergoline:
1. In patients with metastatic breast cancer, oral cabergoline administration at 1 mg twice weekly improved survival rate. [6]
2. Cabergoline administration at 0.5 mg once per week in cancer patients enhanced the efficacy of the classical endocrine therapy for advanced breast cancer. [7-8]
3. In patients with pituitary tumors, cabergoline administration was associated with tumor shrinkage. [9-11]
4. In patients with macroprolactinoma, a benign, noncancerous tumor of the pituitary gland, long-term and low-dose treatment with cabergoline resulted in tumor volume reduction greater than 80%. [12]
5. Studies revealed that cabergoline may be toxic to various types of cancer such as breast, lung, gastric, ovarian, liver, and esophageal cancer, as well as pituitary tumors. [13-18]
6. In rat pituitary tumor cell lines, cabergoline treatment enhanced suppression of cell proliferation. [19]
7. Cabergoline also reduced rat pituitary tumor size by suppressing signaling pathways and inducing cell death. [20]